Genomic BRCA and Extensive ovArian Cancer Testing

Study Overview
=================
Brief Summary
-----------------
This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Detailed Description
-----------------
This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Official Title
-----------------
Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities

Conditions
-----------------
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient older than 18 years. Patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014) Patient in first line therapy Available tumor sample fixed in formalin and included in paraffin (FFPE): in pre-chemotherapy, insofar as possible having a sufficient tumor surface, with a final cellularity of at least 20% Identification of a molecular genetics' cancer platform participant in GREAT and an onco-geneticists team working with the investigator team Patient consenting her data to be collected and submitted through an automated processing Patient beneficiary from the French social security Exclusion Criteria: Patient with a mucinous ovarian carcinoma Patient pregnant or breastfeeding Patient under legal protection (guardianship or court order) or unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between Progression Free Survival (PFS) and the detected tumor genetic abnormalities |  | From baseline until the date of progression or death, which ever occurs earlier, assessed up to 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between age and the detected tumor genetic abnormalities |  | Baseline | 
| Correlation between histology status and the detected tumor genetic abnormalities |  | Baseline | 
| Correlation between FIGO stage and the detected tumor genetic abnormalities |  | Baseline | 
| Correlation between surgery resection status and the detected tumor genetic abnormalities |  | Up to 10 years | 
| Correlation between treatment response and the detected tumor genetic abnormalities |  | Up to 10 years | 
| Correlation between Overall survival (OS) and the detected tumor genetic abnormalities |  | From baseline to death, assessed up to 10 years |